Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
| Revenue (TTM) | $15.53B |
| Gross Profit (TTM) | $6.91B |
| EBITDA | $4.70B |
| Operating Margin | 33.10% |
| Return on Equity | 14.00% |
| Return on Assets | 6.53% |
| Revenue/Share (TTM) | $150.31 |
| Book Value | $316.11 |
| Price-to-Book | 2.60 |
| Price-to-Sales (TTM) | 5.24 |
| EV/Revenue | 4.839 |
| EV/EBITDA | 13.07 |
| Quarterly Earnings Growth (YoY) | -4.50% |
| Quarterly Revenue Growth (YoY) | 16.70% |
| Shares Outstanding | $101.14M |
| Float | $95.85M |
| % Insiders | 2.08% |
| % Institutions | 93.40% |
Volatility is currently contracting
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment
Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. In the first part of the year before we invested, Abbott slightly missed earnings estimates while it was digesting its acquisition of Exact Sciences, along with a variety of turmoil in the medtech and infant nutrition industries. Digital and print publisher People Inc. was a detractor in the quarter, while hospitality and entertainment company MGM Resorts also detracted.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The market is regaining confidence in Avantor's ability to grow organically and in Emmanuel Ligner's turnaround plan. Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. Building products company Fortune Brands Innovations saw its stock price decline in Q3, retracing Q2's positive move related to excitement over Jesse Singh's appointment as CEO.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on REGN and any ticker you trade — then tracks every position and per-strategy win rate.
